TJ037130

TJ037130 is a humanized monoclonal antibody specifically designed to target **Claudin-6 (CLDN6)**, a member of the claudin family of tight junction proteins. CLDN6 is an oncofetal antigen that is highly expressed in various solid tumors—including ovarian, lung, and gastric cancers—while remaining largely absent in normal adult tissues, making it an ideal target for selective cancer therapy. Developed by **I-Mab Hangzhou** (天境生物科技（杭州）有限公司), TJ037130 is designed to bind specifically to the extracellular domains of CLDN6 on tumor cells. This binding is intended to trigger anti-tumor responses, potentially through antibody-dependent cellular cytotoxicity (ADCC) or by disrupting oncogenic signaling pathways associated with CLDN6 overexpression. The agent is currently being investigated in a Phase 1 first-in-human study (CTR20262685) to evaluate its safety, pharmacokinetics, and preliminary clinical activity in patients with CLDN6-positive advanced or metastatic solid tumors.